Cardiotoxicity, Chemotherapeutic Toxicity
Conditions
Keywords
Chemotherapy induced cardiotoxicity, Troponin, Heart failure
Brief summary
In cancer patients, the increase of troponin I soon after chemotherapy is a strong predictor of left ventricular dysfunction and poor cardiologic outcome. This information provides a rationale for the development of prophylactic strategies directed against chemotherapy-induced cardiotoxicity (CTIC). Activation of the renin-angiotensin system has been proved to be involved in the development and progression of cardiac dysfunction in several clinical settings, and has been suggested to have a role in the occurrence of CTIC. We investigated the role of treatment with ACE-inhibitors in the prevention of CTIC in high-risk cancer patients.
Interventions
DRUGEnalapril
enalapril orally administered
Sponsors
European Institute of Oncology
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Consecutive patients undergoing high-dose chemotherapy showing early release of Troponin I
Exclusion criteria
* Contraindication to ACE-inhibitors * On-going therapy with beta-blockers, ACE-inhibitors, angiotensin-receptors blockers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of chemotherapy-induced cardiotoxicity | 12 month period |
Secondary
| Measure | Time frame |
|---|---|
| Major adverse cardiac events, including death. | 12 month period |
Countries
Italy
Outcome results
None listed